Table 3 Example of the REMARK profile illustrated using data from a study of expression of epithelial membrane protein-2 in patients with endometrial adenocarcinoma [158].
From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
a) Patients, treatment and variables | ||||||
|---|---|---|---|---|---|---|
136 Patients with endometrial adenocarcinoma assessed for eligibility, 37 excluded (33 no informative immune histochemistry, 4 without clinical information) | ||||||
99 Patients included, stages IA to IVB | ||||||
Formalin fixed, paraffin embedded endometrial tissue samples, Department of Pathology, UCLA Los Angeles, USA | ||||||
Marker (and how was the marker handled in analysis?) | M = epithelial membrane protein-2 Immunoreactive score obtained by multiplying subscores for intensity (0 to 3+) and distribution of immunoreactivity (0 to 4+) grouped as negative (score 0), weak (1 to 3) or moderate-to-strong (4 to 12) | |||||
Outcomes: | DFS (97 patients, 42 events), OS (99 patients, 32 events) | |||||
Further variables: | v1 = age, v2 = ER, v3 = PR, v4 = vascular invasion, v5 = stage, v6 = histology, v7 = grade | |||||
b) Statistical analyses of survival outcomes | ||||||
| Â | DFS | OS | Â | Â | ||
Aim | Patients | Events | Patients | Events | Variables considered | Results/remarks |
A1: Univariable | 97 | 42 | 99 | 32 | M, v1-v7 | Figure 3, Figure 4, Table 2, Table 3 |
| Â | Â | Â | Â | Â | Â | DFS: except v1 all significant |
| Â | Â | Â | Â | Â | Â | OS: all significant |
A2: Multivariable | 97 | 42 | 99 | 32 | DFS: M, v2-v7 | Table 4, Table 5 |
| Â | Â | Â | Â | Â | OS: M, v1-v7 | In multivariable analysis: all significant in A1, then stepwise selection |
| Â | Â | Â | Â | Â | Â | Variables in final models: DFS: M, v5, v6; OS: v4, v6, v7 (M is not included) |